Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.

ABSTRACT:

Introduction

Hydroxychloroquine (HCQ) for coronavirus disease 2019 (COVID-19) is presently being used off-label or within a clinical trial.

Objectives

We investigated a multinational database of patients with COVID-19 with real-world data containing outcomes and their relationship to HCQ use. The primary outcome was all-cause mortality within 30 days of follow-up.

Methods

This was a retrospective cohort study of patients receiving HCQ within 48 hours of hospital admission. Medications, preexisting conditions, clinical measures on admission, and outcomes were recorded.

Results

Among patients with a diagnosis of COVID-19 in our propensity-matched cohort, the mean ages ± SD were 62.3 ± 15.9 years (53.7% male) and 61.9 ± 16.0 years (53.0% male) in the HCQ and no-HC

SUBMITTER: Annie FH 

PROVIDER: S-EPMC7675747 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature